← Back
$APLS All transactions

Apellis Pharmaceuticals, Inc.

A

$ Value

$1.6M

Shares

82,500

Price

$19

Filed

Jun 11

Insider

Name

DeLong Mark Jeffrey

Title

Chief Business & Strat Officer

CIK

0001856078

Roles

Officer

Transaction Details

Transaction Date

2025-06-09

Code

A

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

82,500

Footnotes

This represents stock option award granted on June 9, 2025, which will vest over a two-year period. Specifically, 50% of the options will vest on each of the one-year and two-year anniversaries of the grant date, contingent upon continued service.

Filing Info

Accession No.

0001127602-25-017275

Form Type

4

Issuer CIK

0001492422

DeLong Mark Jeffrey's History

Date Ticker Type Value
2026-02-11 APLS $8K
2026-01-28 APLS A $0
2026-01-22 APLS $73K
2026-01-20 APLS $26K
2026-01-13 APLS $39K
2025-06-09 APLS A $1.6M

Other Insiders at APLS (90d)

Insider Bought Sold Last
Dolsten Mikael 2026-02-27
Watson David O.
General Counsel
2026-01-28
Deschatelets Pascal
Chief Scientific Officer
2026-01-28
Francois Cedric
Chief Executive Officer
2026-03-11
Sullivan Timothy Eugene
Chief Financial Officer
2026-04-17
O'Brien Stephanie Monaghan 2026-04-06
Nicholson Nur
Chief Technical Officer
2026-01-28
Chopas James George
VP/Chief Accounting Officer
2026-01-28
DeLong Mark Jeffrey
Chief Business & Strat Officer
$8K 2026-02-11
Boucher Kelley
Chief People Officer
2026-01-28
MELTZER LESLIE
Chief Research and Development
2026-01-28